CTOs on the Move

Keros Therapeutics

www.kerostx.com

 
Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.kerostx.com
  • 99 Hayden Avenue
    Lexington, MA USA 02421
  • Phone: 617.314.6297

Executives

Name Title Contact Details

Funding

Keros Therapeutics raised $23M on 01/08/2019
Keros Therapeutics raised $56M on 03/04/2020

Similar Companies

Colorado BioScience Association

Colorado BioScience Association is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orna Therapeutics

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna`s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.

AccuraGen Holdings

We have developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.

Allakos

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company`s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis.

Controle Analytique Inc

Controle Analytique Inc is a Thetford Mines, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.